Managing Jaundice Neonatal
Applies the AAP 2022 Clinical Practice Guideline for the Management of Hyperbilirubinemia in the Newborn Infant ≥ 35 Weeks' Gestation. Structures bilirubin risk assessment using the Bhutani hour-specific nomogram, determines phototherapy and exchange transfusion thresholds based on neurotoxicity risk factors, and guides safe discharge planning with follow-up scheduling.
Why This Skill Exists
Neonatal hyperbilirubinemia affects approximately 60% of term and 80% of preterm newborns. While most jaundice is physiologic, failure to identify and treat pathologic hyperbilirubinemia can result in acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (kernicterus) — an entirely preventable form of brain damage. The AAP 2022 guideline (replacing the 2004 guideline) provides updated, hour-specific phototherapy and exchange transfusion thresholds with explicit neurotoxicity risk factor assessment. This skill enforces the updated protocol.
Checkpoint A — Intake Verification
Required Intake Questions
- What is the infant's gestational age (this guideline applies to ≥ 35 weeks)?
- What is the infant's age in hours (critical for nomogram plotting)?
- What is the maternal and infant blood type and direct Coombs (DAT) result?
- What is the current bilirubin level — total serum bilirubin (TSB) or transcutaneous bilirubin (TcB)?
- Is the infant breastfeeding? How is feeding going (latch, frequency, urine/stool output)?
- What is the infant's current weight and percent weight loss from birth weight?
- Are there any neurotoxicity risk factors present (see Step 2)?
- Has the infant had a prior bilirubin measurement? If so, what was the rate of rise?
Required Documents
- Maternal blood type and antibody screen
- Infant blood type and direct antiglobulin test (DAT/Coombs)
- Serial bilirubin measurements with time stamps (TSB or TcB)
- Birth weight and current weight
- Feeding log (type of feeding, frequency, output)
- G6PD status (if known or if high-risk ethnicity)
TcB is acceptable for screening but if TcB is within 3 mg/dL of the phototherapy threshold, a confirmatory TSB must be obtained.
Step 1 — Bilirubin Measurement and Risk Zone Assignment (Bhutani Nomogram)
Pre-Discharge Bilirubin Assessment
- Obtain TSB or TcB on every newborn before discharge (universal screening per AAP 2022)
- Plot the result on the Bhutani hour-specific bilirubin nomogram
- Assign risk zone:
| Risk Zone |
Percentile Range |
Interpretation |
| Low |
< 40th percentile |
Low risk for subsequent hyperbilirubinemia |
| Low-intermediate |
40th-75th percentile |
Needs follow-up; may not need early recheck |
| High-intermediate |
75th-95th percentile |
Close follow-up required; early recheck |
| High |
> 95th percentile |
At or near phototherapy threshold; may need treatment |
Rate of Rise
- Calculate bilirubin rate of rise if ≥ 2 values available
- Rate > 0.2 mg/dL/hour in first 24 hours is concerning for hemolysis
- Rate > 0.3 mg/dL/hour at any time warrants urgent evaluation
First 24 Hours
- Jaundice visible in the first 24 hours of life is ALWAYS pathologic until proven otherwise
- Obtain TSB immediately and evaluate for hemolytic disease (blood type incompatibility, G6PD deficiency, spherocytosis)
Step 2 — Neurotoxicity Risk Factor Assessment
The AAP 2022 guideline uses neurotoxicity risk factors to adjust phototherapy and exchange transfusion thresholds. Identify the presence of ANY of the following:
Neurotoxicity Hyperbilirubinemia Risk Factors
- Gestational age 35-37 weeks and 6 days (lower GA = higher risk)
- Albumin < 3.0 g/dL
- Isoimmune hemolytic disease (positive DAT — ABO or Rh incompatibility)
- G6PD deficiency
- Significant lethargy or sepsis
- Acidosis (pH < 7.15)
- Instability of clinical condition
Risk Category Assignment
| Category |
Definition |
Phototherapy Threshold Adjustment |
| No risk factors |
GA ≥ 38 weeks, no risk factors |
Standard thresholds |
| With risk factors |
Any neurotoxicity risk factor present |
Lower thresholds (approximately 2 mg/dL lower) |
Step 3 — Phototherapy Initiation
AAP 2022 Phototherapy Thresholds (Hour-Specific)
Thresholds vary by infant age in hours and risk category. Key representative values for term infants without risk factors:
| Age (hours) |
PT Threshold (no risk factors) |
PT Threshold (with risk factors) |
| 24 |
~12 mg/dL |
~10 mg/dL |
| 48 |
~15 mg/dL |
~13 mg/dL |
| 72 |
~18 mg/dL |
~15.5 mg/dL |
| 96+ |
~20 mg/dL |
~17.5 mg/dL |
Use the actual AAP 2022 phototherapy nomogram for precise thresholds at each hour of life — the above are approximate reference points.
Phototherapy Technical Standards
- Intensive phototherapy delivers ≥ 30 µW/cm²/nm in the 430-490 nm wavelength band
- Maximize skin surface area exposure (diaper only, no eye shields blocking forehead)
- Proper eye protection (opaque eye shields, check position frequently)
- Continue breastfeeding during phototherapy (supplement if intake is inadequate)
- Recheck TSB 4-6 hours after initiation; then every 6-12 hours during treatment
- Do NOT use sunlight exposure as a substitute for phototherapy
When to Escalate
- TSB rising despite phototherapy → verify equipment irradiance, increase skin exposure, consider double or triple lights
- TSB approaching exchange transfusion threshold → prepare for potential exchange; notify NICU/transport
Step 4 — Exchange Transfusion Thresholds
Indications for Exchange Transfusion
- TSB exceeds exchange transfusion threshold for age in hours and risk category (approximately 5 mg/dL above phototherapy threshold in most cases)
- TSB fails to decline by 1-2 mg/dL within 4-6 hours of intensive phototherapy and is approaching exchange threshold
- Signs of acute bilirubin encephalopathy (ABE) at ANY bilirubin level
Signs of Acute Bilirubin Encephalopathy (ABE)
Early phase:
- Lethargy, hypotonia, poor suck
Advanced phase:
- Hypertonia (retrocollis, opisthotonos), high-pitched cry, fever
- Any neurologic sign attributable to bilirubin → EMERGENT exchange transfusion regardless of TSB level
Exchange Transfusion Protocol
- Double-volume exchange (160-180 mL/kg) replaces approximately 85% of circulating RBCs
- Reduces TSB by approximately 50%
- Requires NICU setting with continuous monitoring
- Complications: electrolyte disturbances (hypocalcemia, hyperkalemia), thrombocytopenia, NEC, line complications, cardiac arrhythmia
Step 5 — Discharge Planning and Follow-Up
Pre-Discharge Checklist
- Pre-discharge TSB or TcB plotted on Bhutani nomogram with risk zone assigned
- Risk factors documented (blood type, DAT, G6PD if applicable, GA)
- Feeding assessment: latch, frequency, urine/stool output, percent weight loss
Follow-Up Scheduling Based on Risk Zone and Age at Discharge
| Discharge Age |
Risk Zone |
Follow-Up |
| < 24 hours |
Any |
Within 24 hours |
| 24-47.9 hours |
High or high-intermediate |
Within 24 hours |
| 24-47.9 hours |
Low-intermediate or low |
Within 48 hours |
| 48-72 hours |
High or high-intermediate |
Within 24 hours |
| 48-72 hours |
Low-intermediate or low |
Within 48 hours |
Phototherapy Discontinuation
- Discontinue when TSB drops 2-3 mg/dL below the phototherapy threshold for age
- Recheck TSB 12-24 hours after discontinuation (rebound occurs in ~10-15% of cases)
- Higher rebound risk with hemolytic disease and younger gestational age
Breastfeeding Support
- Do NOT discontinue breastfeeding for jaundice management
- Optimize breastfeeding: 8-12 feeds/day, lactation consultation, supplement with expressed breast milk or formula if intake is insufficient
- "Breastfeeding jaundice" (suboptimal intake) is managed by improving breastfeeding, not stopping it
- "Breast milk jaundice" (prolonged indirect hyperbilirubinemia after 1 week) rarely requires intervention; TSB > 20 mg/dL warrants evaluation but does not typically require cessation of breastfeeding
Checkpoint B — Jaundice Management Review
Quality Audit
| Item |
Requirement |
Pass? |
| Universal screening |
Pre-discharge bilirubin obtained on every newborn |
|
| Hour-specific plotting |
TSB/TcB plotted on Bhutani nomogram at exact age in hours |
|
| Risk zone assignment |
Documented low/low-int/high-int/high |
|
| Risk factor assessment |
All neurotoxicity risk factors systematically evaluated |
|
| Threshold accuracy |
Correct phototherapy threshold applied for age and risk |
|
| Phototherapy standards |
Irradiance ≥ 30 µW/cm²/nm documented |
|
| Recheck compliance |
TSB rechecked 4-6 hours after starting phototherapy |
|
| ABE screening |
Neurologic assessment documented |
|
| Follow-up scheduling |
Post-discharge follow-up within guideline timeframe |
|
| No unexplained [VERIFY] tags |
All flagged items resolved or escalated |
|
Guidelines
- Follow AAP 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia in Newborns ≥ 35 Weeks' Gestation (replaces 2004 guideline)
- Use Bhutani hour-specific bilirubin nomogram for pre-discharge risk stratification
- Use AAP 2022 hour-specific phototherapy and exchange transfusion threshold nomograms (separate from Bhutani prediction nomogram)
- G6PD deficiency: AAP recommends universal G6PD screening; if not available, screen high-risk populations (African, Mediterranean, Middle Eastern, Southeast Asian descent)
- TcB is valid for screening but confirm with TSB when within 3 mg/dL of threshold
- Phototherapy irradiance standard: ≥ 30 µW/cm²/nm (intensive) measured at infant skin level
- Do not interrupt breastfeeding for jaundice management — optimize feeding support
- ABE signs mandate emergent exchange transfusion at any TSB level
- Follow AAP safe discharge guidelines: no newborn should be discharged without a bilirubin assessment and follow-up plan
- This skill produces clinical documentation; it does not replace clinical judgment
1---2name: managing-jaundice-neonatal3description: Applies AAP hyperbilirubinemia guidelines with phototherapy thresholds and Bhutani nomogram. Use when managing neonatal jaundice, interpreting bilirubin levels, or determining phototherapy need.4---5
6# Managing Jaundice Neonatal
7
8Applies the AAP 2022 Clinical Practice Guideline for the Management of Hyperbilirubinemia in the Newborn Infant ≥ 35 Weeks' Gestation. Structures bilirubin risk assessment using the Bhutani hour-specific nomogram, determines phototherapy and exchange transfusion thresholds based on neurotoxicity risk factors, and guides safe discharge planning with follow-up scheduling.
9
10## Why This Skill Exists
11
12Neonatal hyperbilirubinemia affects approximately 60% of term and 80% of preterm newborns. While most jaundice is physiologic, failure to identify and treat pathologic hyperbilirubinemia can result in acute bilirubin encephalopathy (ABE) and chronic bilirubin encephalopathy (kernicterus) — an entirely preventable form of brain damage. The AAP 2022 guideline (replacing the 2004 guideline) provides updated, hour-specific phototherapy and exchange transfusion thresholds with explicit neurotoxicity risk factor assessment. This skill enforces the updated protocol.
13
14---
15
16## Checkpoint A — Intake Verification
17
18### Required Intake Questions
191. What is the infant's gestational age (this guideline applies to ≥ 35 weeks)?
202. What is the infant's age in hours (critical for nomogram plotting)?
213. What is the maternal and infant blood type and direct Coombs (DAT) result?
224. What is the current bilirubin level — total serum bilirubin (TSB) or transcutaneous bilirubin (TcB)?
235. Is the infant breastfeeding? How is feeding going (latch, frequency, urine/stool output)?
246. What is the infant's current weight and percent weight loss from birth weight?
257. Are there any neurotoxicity risk factors present (see Step 2)?
268. Has the infant had a prior bilirubin measurement? If so, what was the rate of rise?
27
28### Required Documents
29- Maternal blood type and antibody screen
30- Infant blood type and direct antiglobulin test (DAT/Coombs)
31- Serial bilirubin measurements with time stamps (TSB or TcB)
32- Birth weight and current weight
33- Feeding log (type of feeding, frequency, output)
34- G6PD status (if known or if high-risk ethnicity)
35
36> TcB is acceptable for screening but if TcB is within 3 mg/dL of the phototherapy threshold, a confirmatory TSB must be obtained.
37
38---
39
40## Step 1 — Bilirubin Measurement and Risk Zone Assignment (Bhutani Nomogram)
41
42### Pre-Discharge Bilirubin Assessment
43- Obtain TSB or TcB on every newborn before discharge (universal screening per AAP 2022)
44- Plot the result on the Bhutani hour-specific bilirubin nomogram
45- Assign risk zone:
46
47| Risk Zone | Percentile Range | Interpretation |
48|-----------|-----------------|----------------|
49| Low | < 40th percentile | Low risk for subsequent hyperbilirubinemia |
50| Low-intermediate | 40th-75th percentile | Needs follow-up; may not need early recheck |
51| High-intermediate | 75th-95th percentile | Close follow-up required; early recheck |
52| High | > 95th percentile | At or near phototherapy threshold; may need treatment |
53
54### Rate of Rise
55- Calculate bilirubin rate of rise if ≥ 2 values available
56- Rate > 0.2 mg/dL/hour in first 24 hours is concerning for hemolysis
57- Rate > 0.3 mg/dL/hour at any time warrants urgent evaluation
58
59### First 24 Hours
60- Jaundice visible in the first 24 hours of life is ALWAYS pathologic until proven otherwise
61- Obtain TSB immediately and evaluate for hemolytic disease (blood type incompatibility, G6PD deficiency, spherocytosis)
62
63---
64
65## Step 2 — Neurotoxicity Risk Factor Assessment
66
67The AAP 2022 guideline uses neurotoxicity risk factors to adjust phototherapy and exchange transfusion thresholds. Identify the presence of ANY of the following:
68
69### Neurotoxicity Hyperbilirubinemia Risk Factors
70- Gestational age 35-37 weeks and 6 days (lower GA = higher risk)
71- Albumin < 3.0 g/dL
72- Isoimmune hemolytic disease (positive DAT — ABO or Rh incompatibility)
73- G6PD deficiency
74- Significant lethargy or sepsis
75- Acidosis (pH < 7.15)
76- Instability of clinical condition
77
78### Risk Category Assignment
79| Category | Definition | Phototherapy Threshold Adjustment |
80|----------|-----------|----------------------------------|
81| No risk factors | GA ≥ 38 weeks, no risk factors | Standard thresholds |
82| With risk factors | Any neurotoxicity risk factor present | Lower thresholds (approximately 2 mg/dL lower) |
83
84---
85
86## Step 3 — Phototherapy Initiation
87
88### AAP 2022 Phototherapy Thresholds (Hour-Specific)
89Thresholds vary by infant age in hours and risk category. Key representative values for term infants without risk factors:
90
91| Age (hours) | PT Threshold (no risk factors) | PT Threshold (with risk factors) |
92|-------------|-------------------------------|----------------------------------|
93| 24 | ~12 mg/dL | ~10 mg/dL |
94| 48 | ~15 mg/dL | ~13 mg/dL |
95| 72 | ~18 mg/dL | ~15.5 mg/dL |
96| 96+ | ~20 mg/dL | ~17.5 mg/dL |
97
98> Use the actual AAP 2022 phototherapy nomogram for precise thresholds at each hour of life — the above are approximate reference points.
99
100### Phototherapy Technical Standards
101- Intensive phototherapy delivers ≥ 30 µW/cm²/nm in the 430-490 nm wavelength band
102- Maximize skin surface area exposure (diaper only, no eye shields blocking forehead)
103- Proper eye protection (opaque eye shields, check position frequently)
104- Continue breastfeeding during phototherapy (supplement if intake is inadequate)
105- Recheck TSB 4-6 hours after initiation; then every 6-12 hours during treatment
106- Do NOT use sunlight exposure as a substitute for phototherapy
107
108### When to Escalate
109- TSB rising despite phototherapy → verify equipment irradiance, increase skin exposure, consider double or triple lights
110- TSB approaching exchange transfusion threshold → prepare for potential exchange; notify NICU/transport
111
112---
113
114## Step 4 — Exchange Transfusion Thresholds
115
116### Indications for Exchange Transfusion
117- TSB exceeds exchange transfusion threshold for age in hours and risk category (approximately 5 mg/dL above phototherapy threshold in most cases)
118- TSB fails to decline by 1-2 mg/dL within 4-6 hours of intensive phototherapy and is approaching exchange threshold
119- Signs of acute bilirubin encephalopathy (ABE) at ANY bilirubin level
120
121### Signs of Acute Bilirubin Encephalopathy (ABE)
122Early phase:
123- Lethargy, hypotonia, poor suck
124Advanced phase:
125- Hypertonia (retrocollis, opisthotonos), high-pitched cry, fever
126- Any neurologic sign attributable to bilirubin → EMERGENT exchange transfusion regardless of TSB level
127
128### Exchange Transfusion Protocol
129- Double-volume exchange (160-180 mL/kg) replaces approximately 85% of circulating RBCs
130- Reduces TSB by approximately 50%
131- Requires NICU setting with continuous monitoring
132- Complications: electrolyte disturbances (hypocalcemia, hyperkalemia), thrombocytopenia, NEC, line complications, cardiac arrhythmia
133
134---
135
136## Step 5 — Discharge Planning and Follow-Up
137
138### Pre-Discharge Checklist
139- Pre-discharge TSB or TcB plotted on Bhutani nomogram with risk zone assigned
140- Risk factors documented (blood type, DAT, G6PD if applicable, GA)
141- Feeding assessment: latch, frequency, urine/stool output, percent weight loss
142
143### Follow-Up Scheduling Based on Risk Zone and Age at Discharge
144| Discharge Age | Risk Zone | Follow-Up |
145|---------------|-----------|-----------|
146| < 24 hours | Any | Within 24 hours |
147| 24-47.9 hours | High or high-intermediate | Within 24 hours |
148| 24-47.9 hours | Low-intermediate or low | Within 48 hours |
149| 48-72 hours | High or high-intermediate | Within 24 hours |
150| 48-72 hours | Low-intermediate or low | Within 48 hours |
151
152### Phototherapy Discontinuation
153- Discontinue when TSB drops 2-3 mg/dL below the phototherapy threshold for age
154- Recheck TSB 12-24 hours after discontinuation (rebound occurs in ~10-15% of cases)
155- Higher rebound risk with hemolytic disease and younger gestational age
156
157### Breastfeeding Support
158- Do NOT discontinue breastfeeding for jaundice management
159- Optimize breastfeeding: 8-12 feeds/day, lactation consultation, supplement with expressed breast milk or formula if intake is insufficient
160- "Breastfeeding jaundice" (suboptimal intake) is managed by improving breastfeeding, not stopping it
161- "Breast milk jaundice" (prolonged indirect hyperbilirubinemia after 1 week) rarely requires intervention; TSB > 20 mg/dL warrants evaluation but does not typically require cessation of breastfeeding
162
163---
164
165## Checkpoint B — Jaundice Management Review
166
167- [ ] TSB or TcB obtained with exact time stamp and infant age in hours
168- [ ] Bilirubin plotted on Bhutani nomogram with risk zone documented
169- [ ] Rate of rise calculated (if ≥ 2 values available)
170- [ ] Neurotoxicity risk factors systematically assessed and documented
171- [ ] Phototherapy threshold correctly identified for age and risk category
172- [ ] If phototherapy initiated: irradiance verified, recheck interval set
173- [ ] Exchange transfusion threshold identified; team aware if TSB approaching
174- [ ] ABE signs assessed and documented (lethargy, tone, cry, feeding)
175- [ ] Breastfeeding status assessed with plan for optimization
176- [ ] Discharge follow-up scheduled per risk zone
177- [ ] All [VERIFY] flags resolved or escalated
178
179---
180
181## Quality Audit
182
183| Item | Requirement | Pass? |
184|------|-------------|-------|
185| Universal screening | Pre-discharge bilirubin obtained on every newborn | |
186| Hour-specific plotting | TSB/TcB plotted on Bhutani nomogram at exact age in hours | |
187| Risk zone assignment | Documented low/low-int/high-int/high | |
188| Risk factor assessment | All neurotoxicity risk factors systematically evaluated | |
189| Threshold accuracy | Correct phototherapy threshold applied for age and risk | |
190| Phototherapy standards | Irradiance ≥ 30 µW/cm²/nm documented | |
191| Recheck compliance | TSB rechecked 4-6 hours after starting phototherapy | |
192| ABE screening | Neurologic assessment documented | |
193| Follow-up scheduling | Post-discharge follow-up within guideline timeframe | |
194| No unexplained [VERIFY] tags | All flagged items resolved or escalated | |
195
196---
197
198## Guidelines
199
200- Follow AAP 2022 Clinical Practice Guideline for Management of Hyperbilirubinemia in Newborns ≥ 35 Weeks' Gestation (replaces 2004 guideline)
201- Use Bhutani hour-specific bilirubin nomogram for pre-discharge risk stratification
202- Use AAP 2022 hour-specific phototherapy and exchange transfusion threshold nomograms (separate from Bhutani prediction nomogram)
203- G6PD deficiency: AAP recommends universal G6PD screening; if not available, screen high-risk populations (African, Mediterranean, Middle Eastern, Southeast Asian descent)
204- TcB is valid for screening but confirm with TSB when within 3 mg/dL of threshold
205- Phototherapy irradiance standard: ≥ 30 µW/cm²/nm (intensive) measured at infant skin level
206- Do not interrupt breastfeeding for jaundice management — optimize feeding support
207- ABE signs mandate emergent exchange transfusion at any TSB level
208- Follow AAP safe discharge guidelines: no newborn should be discharged without a bilirubin assessment and follow-up plan
209- This skill produces clinical documentation; it does not replace clinical judgment
CaseMark